Background
==========

Retinal detachment (RD) occurs when the neurosensory retina layer separates from the retinal pigment epithelium. RD involving the foveal center can lead to profound loss of vision \[[@b1-medscimonit-26-e919871]\]. In most cases, RD occurs following a full thickness retinal break, allowing the ingress of fluid from the vitreous cavity to the subretinal space, which can result in retinal separation and is so-called "rhegmatogenous" \[[@b1-medscimonit-26-e919871],[@b2-medscimonit-26-e919871]\]. A systematic review showed that rhegmatogenous RD incidence varied between 6.3 and 17.9 per 100 000 population, and was strongly associated with myopia, increasing age and certain vitreoretinal degenerations \[[@b3-medscimonit-26-e919871]\]. In addition to the loss of photoreceptors following RD, an inflammatory response also develops. RD triggers cell migration and proliferation and production of extracellular matrix proteins, which in turn results in the accumulation of vitreal and periretinal membranes, both hallmarks of proliferative vitreoretinopathy (PVR) \[[@b4-medscimonit-26-e919871]\]. In total, PVR occurs in 5--10% RD cases \[[@b5-medscimonit-26-e919871]\]. PVR can be detected during the late presentation of RD and complicate the post-operative period after a surgery for RD, leading to a re-detachment or limiting visual recovery \[[@b6-medscimonit-26-e919871],[@b7-medscimonit-26-e919871]\]. Clinical studies using adjuvant therapy for the treatment of PVR have been conducted, including anti-inflammatory agents, anti-neoplastic/anti-proliferative agents, anti-growth factor pathway inhibitors and antioxidants, etc. \[[@b6-medscimonit-26-e919871],[@b8-medscimonit-26-e919871]--[@b11-medscimonit-26-e919871]\]. However, the results are often contradictory or inconclusive with only limited success.

Long non-coding RNA (lncRNA) is a group of non-coding transcripts 200--10 000 bp in length but lacks significant protein-coding capacity. They interact in a regulatory manner before, during and after transcription \[[@b12-medscimonit-26-e919871]\]. Salmena et al. made a competing endogenous RNA (ceRNA) hypothesis that lncRNA, mRNA and other RNAs might act as microRNA (miRNA) sponges to inhibit miRNA function through sharing the miRNA response elements (MREs), which is a complicated post-transcriptional regulatory network \[[@b13-medscimonit-26-e919871]\]. There is much evidence to support this hypothesis \[[@b14-medscimonit-26-e919871]--[@b16-medscimonit-26-e919871]\]. On one hand, miRNAs can combine with their target mRNAs and inhibit their expression in the ceRNA network. On the other hand, lncRNA can regulate gene encoding protein level and following cell biology by competing with miRNAs \[[@b15-medscimonit-26-e919871],[@b16-medscimonit-26-e919871]\]. Besides, each miRNA can influence up to hundreds of expressions of transcription, while each RNA transcription with different MREs can be targeted by multiple miRNAs \[[@b16-medscimonit-26-e919871],[@b17-medscimonit-26-e919871]\].

In recent years, a growing number of studies have proven that the lncRNA-miRNA-mRNA regulation network is involved in the course of many diseases, including the tumors, Alzheimer disease and dermatitis etc. \[[@b12-medscimonit-26-e919871],[@b16-medscimonit-26-e919871],[@b18-medscimonit-26-e919871],[@b19-medscimonit-26-e919871]\]. However, whether the ceRNA network takes part in human detached retinas with PVR has not been studied. Here, we downloaded expression data from Gene Expression Omnibust (GEO) database (GSE28133). It contained 19 specimens from patients for severe retinal detachment with PVR and 19 normal control retina specimens from postmortem donors. Bioinformatics analysis and the ceRNA network were conducted to explore the pathological mechanism and potential therapeutic targets of retinal detachment with PVR.

Material and Methods
====================

Tissue samples from the GEO database and bioinformatics analysis
----------------------------------------------------------------

The RNA expression data of tissue samples were obtained from GEO database. The dataset (GSE28133) contained 19 specimens from patients for severe retinal detachment with PVR and 19 normal control retina specimens from postmortem donors. Clinical and pathological features of patients were described \[[@b2-medscimonit-26-e919871]\]. All the samples were analyzed using Affymetrix Human Genome U133 Plus 2.0 Array.

Differentially expressed gene analysis
--------------------------------------

We used the "limma" package in R software to identify the differentially expressed genes (lncRNAs and mRNAs) between human detached retinas with PVR and the control group, with \|log~2~FoldChange (FC)\|\>1.0 and adjusted *P*-value \<0.05. Besides, mRNA and lncRNA annotation was performed using the Encyclopedia of DNA Elements (ENCODE) with ENSEMBL.

GO and KEGG functional enrichment analysis
------------------------------------------

To understand the potential biological functions and processes of differentially expressed genes, Gene Ontology database (GO, *<http://www.geneontology.org>*) and Kyoto Encyclopedia of Genes and Genomes (KEGG, *<http://www.kegg.jp/>*), as well as the "clusterProfilerGO" package and "clusterProfilerKEGG" in R software, were utilized to perform GO and KEGG pathway analysis. Records with *P*-value \<0.05 and enrichment \>2.0 were preserved.

Construction of the lncRNA-miRNA-mRNA ceRNA and protein--protein interaction (PPI) networks
-------------------------------------------------------------------------------------------

Based on the hypothesis that lncRNA could sponge the common miRNA and thus prevent miRNA from binding to their target genes \[[@b20-medscimonit-26-e919871]\], a ceRNA network was constructed. The mircode database (*<http://www.mircode.org/>*) was used for lncRNA to predict their targeted miRNAs. The miRNA-mRNA interactions were predicted by the miRTarBase (*<http://mirtarbase.mbc.nctu.edu.tw/>*), miRDB (*<http://www.mirdb.org/>*) and TargetScan (*<http://www.targetscan.org/>*). Finally, the predicted mRNAs were cross matched with the differentially expressed ones, and the mRNA with no negatively regulated lncRNA or miRNA were abandoned. The lncRNA, miRNA and mRNA with \|log~2~FC\| \>1.0 and adjusted *P*-value \<0.05 were preserved. Construction and visualization of the lncRNA-miRNA-mRNA ceRNA network were conducted using Cytoscape v3.6.1. Besides, PPI network of mRNAs involved in the ceRNA network was set up with high confidence (0.700) by String (*<https://string-db.org/>*).

Results
=======

Differentially expressed lncRNAs and mRNAs between the human detached retinas with PVR and normal controls
----------------------------------------------------------------------------------------------------------

Clinical characteristics of patients were described in the previous study \[[@b2-medscimonit-26-e919871]\]. In total, 994 genes were significantly changed between human detached retinas with PVR and normal human retinas with thresholds of \|log~2~FC\| \>1.0 and adjusted *P*-value \<0.05, as is shown in the volcano map ([Figure 1A](#f1-medscimonit-26-e919871){ref-type="fig"}). Among them, 23 genes were lncRNA, with 16 genes downregulated and 7 genes upregulated. The aberrantly expressed lncRNAs can be viewed in the heatmap ([Figure 1B](#f1-medscimonit-26-e919871){ref-type="fig"}) and their gene IDs and log~2~FC are listed ([Table 1](#t1-medscimonit-26-e919871){ref-type="table"}), in which the 9 lncRNAs taking part in the ceRNA network were marked with asterisk keys. Besides, 971 mRNAs were identified as differentially expressed in which 655 (67.46%) were upregulated and 316 (32.54%) were downregulated. The differentially expressed mRNA levels were also presented in the heatmap ([Figure 1C](#f1-medscimonit-26-e919871){ref-type="fig"}).

Functional enrichment analysis of differentially expressed mRNAs
----------------------------------------------------------------

GO and KEGG pathway analyses allow for the molecular function and signal pathway annotation of dysregulated mRNAs. Records with *P*-value \<0.05 and enrichment \>2.0 were preserved. The complete list of the 74 terms of GO analysis is presented in [Supplementary Table 1](#s1-medscimonit-26-e919871){ref-type="supplementary-material"}. The top 20 GO terms were visualized in the bubble diagram and the most enriched pathways were the cell adhesion molecule binding (GO: 0050839), actin binding (GO: 0003779) and enzyme inhibitor activity (GO: 0004857), which contained 60, 49, and 44 genes respectively. As shown in [Figure 2A](#f2-medscimonit-26-e919871){ref-type="fig"}), 13 GO terms of the top 20 took part in the binding function of the cell.

The KEGG pathway analysis indicated that 39 pathways were associated with differentially expressed mRNAs ([Supplementary Table 2](#s2-medscimonit-26-e919871){ref-type="supplementary-material"}). The top 20 KEGG pathways enriched are visualized in the bubble diagram ([Figure 2B](#f2-medscimonit-26-e919871){ref-type="fig"}). It shows that infection probably played an important role in retinal detachment with PVR, including human papillomavirus, Epstein-Barr virus, human cytomegalovirus, as well as tuberculosis, etc. In addition, phagosome, focal adhesion, and complement and coagulation cascade were also suggested as participate in PVR progress, containing 32, 29, and 22 genes respectively.

Construction of a ceRNA network and PPI network in the human detached retinas with PVR
--------------------------------------------------------------------------------------

To further understand how lncRNA regulates mRNA through combining with miRNA in human detached retinas with PVR, a lncRNA-miRNA-mRNA (ceRNA) network was constructed. Consequently, we found that 9 lncRNAs interacted with the 27 miRNAs in the ceRNA network using the miRcode database ([Table 2](#t2-medscimonit-26-e919871){ref-type="table"}). A total of 1269 miRNA-targeted mRNAs based on the 27 miRNAs was predicted through miRDB, miRTarBase, and TargetScan databases. MiRNA-targeted mRNAs which were not contained in the differentially expressed mRNAs, which were discarded, and the 73 mutual mRNAs which were preserved ([Figure 3A](#f3-medscimonit-26-e919871){ref-type="fig"}, [Table 3](#t3-medscimonit-26-e919871){ref-type="table"}). Finally, 9 lncRNAs, 27 miRNAs, and 73 mRNAs constituted the ceRNA network ([Figure 4](#f4-medscimonit-26-e919871){ref-type="fig"}). Besides, KEEG pathways enriched by mRNAs in ceRNA network showed that most of them were bound with the PI3K-Akt signaling pathway and human cytomegalovirus infection ([Figure 3B](#f3-medscimonit-26-e919871){ref-type="fig"}). The PPI network constructed for the 73 mRNAs furnished 21 genes with high confidence 0.700 ([Figure 3C](#f3-medscimonit-26-e919871){ref-type="fig"}).

Discussion
==========

PVR is known to complicate the post-operative period after a surgery for RD, leading to a re-detachment or limiting visual recovery. Traditional adjuvant therapy included anti-proliferative agents, anti-inflammatory agents, and anti-growth factor pathway inhibitors. But so far, studies for the treatment of PVR report limited success \[[@b6-medscimonit-26-e919871],[@b8-medscimonit-26-e919871]--[@b11-medscimonit-26-e919871]\]. The previous study detected expression profile of 19 PVR patients and controls, but only focused on part of differentially expressed mRNAs \[[@b2-medscimonit-26-e919871]\]. Neither GO and KEGG functional analysis nor construction of ceRNA network were established. Thus, we re-analyzed the published microarray data of GEO database (GSE28133).

In our analysis, we found 971 mRNAs significantly differentially expressed in the human detached retinas with PVR compared to normal human retinas. The GO pathways enriched by the differentially expressed mRNA showed that main pathways of the top 20 took part in the binding function of the cell, such as cell adhesion molecule binding which contained CLIC1 (logFC=2.76), S100A11 (logFC=4.31) and ICAM1 (logFC=3.06), etc. Chloride intracellular channel 1 (CLIC1), and S100 calcium-binding protein A11 (S100A11) were positively correlated with cell proliferation, invasion, and migration and angiogenesis \[[@b21-medscimonit-26-e919871],[@b22-medscimonit-26-e919871]\]. Intercellular adhesion molecule-1 (ICAM1) is involved in the adhesion of leukocytes to the blood vessel wall \[[@b23-medscimonit-26-e919871]\]. Such significantly dysregulated genes involved in cell adhesion and binding function may have an important role in PVR pathogenesis and deserve more exploration. The KEGG pathways showed that infection and Phosphoinositide 3-kinase (PI3K)-Akt signaling pathway come out in front in RD tissues with PVR. Cytomegalovirus, chlamydia trachomatis, and human immunodeficiency virus have been confirmed in many RD cases \[[@b24-medscimonit-26-e919871]--[@b27-medscimonit-26-e919871]\]. These are in conformance with our analysis and remind us of necessary etiological detection for tissues in vitreous cavity and possible targeted treatment. PI3K plays a crucial role as a mediator of growth factor signaling, cell proliferation, cell survival, and apoptotic inhibition. As the major component of the extracellular matrix in PVR, type I collagen was found to be regulated by the PI3K/Akt pathway in human retinal pigment epithelial cells \[[@b28-medscimonit-26-e919871]\]. Treatment targeting PI3K/Akt pathway to prevent PVR after surgery is worth being studied.

The miRNA is an extensive class of endogenous, noncoding and single-strand RNAs with 18--24 nucleotides that negatively regulates gene expression through interacting with the 30-untranslated regions (30UTR) of their target mRNAs \[[@b29-medscimonit-26-e919871]\]. Thus, miRNAs have essential roles in homeostasis and pathogenesis \[[@b29-medscimonit-26-e919871]\]. In the eye, various miRNAs could act on the retina and have an important role in neuroprotection and angiogenesis \[[@b30-medscimonit-26-e919871]--[@b32-medscimonit-26-e919871]\]. In our analysis, 27 miRNAs were predicted by the 9 lncRNAs in the ceRNA network using the miRcode database. MiR-107, miR-125a-5p, miR-17-5p, miR-20b-5p, and miR-27a-3p interrelated with 7 or more protein-coding genes, which may play a more important role in ceRNA network. These aberrantly expressed miRNAs also played key roles in multiple biological processes of various diseases \[[@b33-medscimonit-26-e919871]--[@b35-medscimonit-26-e919871]\]. For example, miR-107 was reported to inhibit cell migration and invasion by modulating Notch2 expression and regulate autophagy and apoptosis by targeting TRAF3 \[[@b36-medscimonit-26-e919871],[@b37-medscimonit-26-e919871]\]. However, the influence of these miRNAs on PVR is rarely explained.

Compared with protein-coding genes and miRNAs, lncRNAs have significant advantages as prognostic biomarkers or therapeutic targets \[[@b38-medscimonit-26-e919871],[@b39-medscimonit-26-e919871]\]. LncRNA regulates gene encoding protein level and participates in the regulation of cell biology through competing with miRNAs in the ceRNA network. There were 23 lncRNAs that were detected to be significantly differentially expressed in the human detached retinas with PVR and 9 of them were involved in the ceRNA network. The most upregulated lncRNA in the ceRNA network is reported to be HCP5. HCP5 was reported to express mainly in the immune system and often considered to be associated with herpes zoster and cancers \[[@b40-medscimonit-26-e919871],[@b41-medscimonit-26-e919871]\]. HCP5 can promote cancer via the PI3K/AKT pathway, which was found to be the most enriched in the KEGG pathways by mRNAs in the ceRNA network \[[@b40-medscimonit-26-e919871]\]. In our analysis, HCP5 was also predicted to interact with 16 miRNAs. Other notable lncRNAs in the ceRNA network reported have included TDRG1 and MIAT \[[@b42-medscimonit-26-e919871],[@b43-medscimonit-26-e919871]\]. TDRG was reported to promote the proliferation and progression of cells through PI3K/Akt/mTOR signaling \[[@b42-medscimonit-26-e919871]\]. Targeting MIAT was found to protect against myocardial hypoxia/reoxygenation injury, but its function in RD and PVR has not been studied \[[@b43-medscimonit-26-e919871]\]. In addition, MALAT1 was also found to be significantly upregulated in the fibrovascular membranes and the peripheral blood samples of PVR patients. *In vitro* studies revealed a critical role of MALAT1 in RPE proliferation and migration \[[@b44-medscimonit-26-e919871]\]. However, studies that focus on the function of lncRNA as miRNA sponges in human RD and PVR are in deficiency.

Our analysis revealed how specific lncRNAs interact with miRNAs and mRNAs through the successful construction of a lncRNA-miRNA-mRNA network in human detached retinas with PVR. This may reveal unknown pathological mechanisms of RD with PVR, which may help to provide potential therapeutic targets. However, we did not conduct quantitative real-time polymerase chain reaction analysis to validate the results of our bioinformatics analysis. The results would be more convincing with such verification experiments.

Conclusions
===========

We demonstrated the differential expression profiles of lncRNAs, and we constructed a lncRNA-associated ceRNA network in human retinal detachment with PVR. Our analysis may contribute to increased understanding of the pathogenesis of human retinal detachment with PVR and provide novel lncRNAs as potential therapeutic targets.

Supplementary Data
==================

###### 

GO pathways enriched by the differentially expressed coding genes.

  ID            Description                                                                         Count   P-value
  ------------- ----------------------------------------------------------------------------------- ------- ----------
  GO: 0005201   Extracellular matrix structural constituent                                         22      2.10E-11
  GO: 0005178   Integrin binding                                                                    26      1.92E-10
  GO: 0050839   Cell adhesion molecule binding                                                      60      2.62E-10
  GO: 0019838   Growth factor binding                                                               26      2.98E-09
  GO: 0003779   Actin binding                                                                       49      2.78E-08
  GO: 0042605   Peptide antigen binding                                                             11      5.64E-08
  GO: 0061134   Peptidase regulator activity                                                        31      2.34E-07
  GO: 0004857   Enzyme inhibitor activity                                                           44      1.17E-06
  GO: 0061135   Endopeptidase regulator activity                                                    25      4.70E-06
  GO: 0048407   Platelet-derived growth factor binding                                              6       6.50E-06
  GO: 0042277   Peptide binding                                                                     32      1.06E-05
  GO: 0033218   Amide binding                                                                       34      2.05E-05
  GO: 0004866   Endopeptidase inhibitor activity                                                    23      2.51E-05
  GO: 0051015   Actin filament binding                                                              23      2.76E-05
  GO: 0044548   S100 protein binding                                                                6       3.70E-05
  GO: 0005539   glycosaminoglycan binding                                                           26      4.10E-05
  GO: 0002020   Protease binding                                                                    19      4.63E-05
  GO: 0008201   Heparin binding                                                                     21      5.60E-05
  GO: 0030414   Peptidase inhibitor activity                                                        23      5.65E-05
  GO: 0008191   Metalloendopeptidase inhibitor activity                                             6       5.90E-05
  GO: 0005518   Collagen binding                                                                    12      7.07E-05
  GO: 0023026   MHC class II protein complex binding                                                6       9.03E-05
  GO: 0031406   Carboxylic acid binding                                                             23      0.000101
  GO: 0043177   Organic acid binding                                                                23      0.000119
  GO: 0019864   IgG binding                                                                         5       0.000123
  GO: 0016641   Oxidoreductase activity, acting on the CH-NH2 group of donors, oxygen as acceptor   6       0.000133
  GO: 0004859   Phospholipase inhibitor activity                                                    5       0.000202
  GO: 0019955   Cytokine binding                                                                    15      0.000229
  GO: 0001968   Fibronectin binding                                                                 7       0.000249
  GO: 0030507   Spectrin binding                                                                    7       0.000249
  GO: 0050840   Extracellular matrix binding                                                        10      0.000259
  GO: 0008020   G-protein coupled photoreceptor activity                                            5       0.000315
  GO: 0023023   MHC protein complex binding                                                         6       0.000366
  GO: 0005504   Fatty acid binding                                                                  7       0.00041
  GO: 0030674   Protein binding, bridging                                                           20      0.000439
  GO: 0016504   Peptidase activator activity                                                        8       0.000464
  GO: 0005520   Insulin-like growth factor binding                                                  7       0.000517
  GO: 0005546   Phosphatidylinositol-4,5-bisphosphate binding                                       11      0.000544
  GO: 0030246   Carbohydrate binding                                                                27      0.000547
  GO: 0016638   Oxidoreductase activity, acting on the CH-NH2 group of donors                       6       0.000646
  GO: 0019865   Immunoglobulin binding                                                              6       0.000646
  GO: 0009881   Photoreceptor activity                                                              5       0.000674
  GO: 0070492   Oligosaccharide binding                                                             5       0.00094
  GO: 0033293   Monocarboxylic acid binding                                                         10      0.000973
  GO: 0042578   Phosphoric ester hydrolase activity                                                 33      0.001054
  GO: 0046982   Protein heterodimerization activity                                                 42      0.001109
  GO: 0019203   Carbohydrate phosphatase activity                                                   4       0.001111
  GO: 0035325   Toll-like receptor binding                                                          4       0.001111
  GO: 0050308   Sugar-phosphatase activity                                                          4       0.001111
  GO: 0008329   Signaling pattern recognition receptor activity                                     5       0.001276
  GO: 0038187   Pattern recognition receptor activity                                               5       0.001276
  GO: 0055102   Lipase inhibitor activity                                                           5       0.001276
  GO: 0019956   Chemokine binding                                                                   6       0.001345
  GO: 0015298   Solute: cation antiporter activity                                                  7       0.001425
  GO: 0004197   Cysteine-type endopeptidase activity                                                12      0.001529
  GO: 0071949   FAD binding                                                                         6       0.001673
  GO: 0050786   RAGE receptor binding                                                               4       0.001676
  GO: 0043531   ADP binding                                                                         7       0.001704
  GO: 0060090   Molecular adaptor activity                                                          20      0.001883
  GO: 0005507   Copper ion binding                                                                  9       0.00199
  GO: 0003785   Actin monomer binding                                                               6       0.00206
  GO: 1901681   Sulfur compound binding                                                             23      0.002196
  GO: 0098641   Cadherin binding involved in cell-cell adhesion                                     5       0.002201
  GO: 0001540   Amyloid-beta binding                                                                9       0.002258
  GO: 0036041   Long-chain fatty acid binding                                                       4       0.002413
  GO: 0045296   Cadherin binding                                                                    29      0.002488
  GO: 0043394   Proteoglycan binding                                                                7       0.002799
  GO: 0031994   Insulin-like growth factor i binding                                                4       0.003346
  GO: 0032561   Guanyl ribonucleotide binding                                                       33      0.003348
  GO: 0019001   Guanyl nucleotide binding                                                           33      0.003483
  GO: 0001848   Complement binding                                                                  5       0.003539
  GO: 0098631   Cell adhesion mediator activity                                                     7       0.003784
  GO: 0015297   Antiporter activity                                                                 11      0.003925
  GO: 0008236   Serine-type peptidase activity                                                      25      0.004086

###### 

KEGG pathways enriched by the differentially expressed coding genes.

  ID         Description                                                              Count   *P*-value
  ---------- ------------------------------------------------------------------------ ------- -----------
  hsa04744   Phototransduction                                                        17      1.47E-14
  hsa05150   Staphylococcus aureus infection                                          21      1.87E-10
  hsa04145   Phagosome                                                                32      2.46E-10
  hsa04610   Complement and coagulation cascades                                      22      6.39E-10
  hsa05169   Epstein-Barr virus infection                                             34      2.67E-08
  hsa05152   Tuberculosis                                                             31      6.42E-08
  hsa05145   Toxoplasmosis                                                            23      1.69E-07
  hsa05133   Pertussis                                                                18      3.54E-07
  hsa04612   Antigen processing and presentation                                      18      4.37E-07
  hsa05140   Leishmaniasis                                                            17      1.19E-06
  hsa05167   Kaposi sarcoma-associated herpesvirus infection                          29      1.68E-06
  hsa05146   Amoebiasis                                                               19      3.14E-06
  hsa04512   ECM-receptor interaction                                                 17      5.38E-06
  hsa04510   Focal adhesion                                                           29      6.69E-06
  hsa04933   AGE-RAGE signaling pathway in diabetic complications                     18      2.26E-05
  hsa04940   Type I diabetes mellitus                                                 11      3.20E-05
  hsa05165   Human papillomavirus infection                                           38      6.93E-05
  hsa05163   Human cytomegalovirus infection                                          29      7.05E-05
  hsa04974   Protein digestion and absorption                                         16      7.51E-05
  hsa05134   Legionellosis                                                            12      7.74E-05
  hsa05164   Influenza A                                                              24      7.76E-05
  hsa05132   Salmonella infection                                                     15      0.000157
  hsa05166   Human T-cell leukemia virus 1 infection                                  27      0.000263
  hsa04514   Cell adhesion molecules (CAMs)                                           20      0.00035
  hsa05144   Malaria                                                                  10      0.00054
  hsa04151   PI3K-Akt signaling pathway                                               37      0.000605
  hsa05170   Human immunodeficiency virus 1 infection                                 25      0.000858
  hsa04210   Apoptosis                                                                18      0.001211
  hsa04380   Osteoclast differentiation                                               17      0.00158
  hsa04672   Intestinal immune network for IgA production                             9       0.002223
  hsa04670   Leukocyte transendothelial migration                                     15      0.002691
  hsa05014   Amyotrophic lateral sclerosis (ALS)                                      9       0.00296
  hsa04010   MAPK signaling pathway                                                   30      0.002984
  hsa04218   Cellular senescence                                                      19      0.003215
  hsa05130   Pathogenic Escherichia coli infection                                    9       0.005004
  hsa04650   Natural killer cell mediated cytotoxicity                                16      0.005015
  hsa05160   Hepatitis C                                                              18      0.005171
  hsa00532   Glycosaminoglycan biosynthesis -- chondroitin sulfate/dermatan sulfate   5       0.005557
  hsa04142   Lysosome                                                                 15      0.006575
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![Differentially expressed genes between the human detached retinas with PVR and normal controls. (**A**) The volcano plot of the differently expressed genes. The x axis is -log10(adjusted *P-*value) while the y axis is log~2~FC. Black dots indicated non-differently expressed genes. The red dots indicate upregulated genes while the green dots indicate downregulated ones. (**B**) Heatmap of differently expressed lncRNAs. (**C**) Heatmap of differently expressed mRNAs. (**B, C**) The x axis is for the sample serial number and the y axis is for the differentially expressed gene. Red blocks represent upregulation and green blocks represent downregulation.](medscimonit-26-e919871-g001){#f1-medscimonit-26-e919871}

![Functional enrichment analysis of differentially expressed mRNAs in the human detached retinas with PVR. (**A**) Top 20 most significant biological processes in GO analysis. (**B**) Top 20 most significant KEGG pathways.](medscimonit-26-e919871-g002){#f2-medscimonit-26-e919871}

![mRNAs in ceRNA network. (**A**) Venn diagram of differentially expressed mRNAs in ceRNA network. (**B**) KEEG pathways enriched by mRNAs in ceRNA network. (**C**) The protein-protein interaction network constructed for mRNA involved in ceRNA network.](medscimonit-26-e919871-g003){#f3-medscimonit-26-e919871}

![CeRNA network in human detached retinas with PVR. Diamonds represent lncRNAs, triangles represent miRNAs and rounds represent protein-coding genes. Gray edges indicate lncRNA-miRNA-mRNA interactions.](medscimonit-26-e919871-g004){#f4-medscimonit-26-e919871}

###### 

Dysregulated lncRNAs between human detached retinas with PVR and normal controls.

  lncRNA                                                              Gene ID     Expression change   logFC (PVR/N)   Adj. *P*-value
  ------------------------------------------------------------------- ----------- ------------------- --------------- ----------------
  HCP5[\*](#tfn2-medscimonit-26-e919871){ref-type="table-fn"}         10866       Up-regulation       1.947938297     1.53E-09
  LINC00623                                                           728855      Up-regulation       1.230129889     5.99E-08
  LINC01094                                                           100505702   Up-regulation       1.217325671     5.36E-06
  PSMB8-AS1                                                           100507463   Up-regulation       1.210172661     1.66E-16
  MIAT[\*](#tfn2-medscimonit-26-e919871){ref-type="table-fn"}         440823      Up-regulation       1.209215343     1.06E-06
  CRNDE[\*](#tfn2-medscimonit-26-e919871){ref-type="table-fn"}        643911      Up-regulation       1.055524554     1.51E-08
  BLACAT1                                                             101669762   Up-regulation       1.048582535     9.62E-07
  ZNF571-AS1                                                          100507433   Down-regulation     −1.031576283    1.01E-06
  AP000462[\*](#tfn2-medscimonit-26-e919871){ref-type="table-fn"}     \-\--       Down-regulation     −1.066771719    0.000173
  SH3BP5-AS1                                                          100505696   Down-regulation     −1.08329906     4.33E-07
  JPX[\*](#tfn2-medscimonit-26-e919871){ref-type="table-fn"}          554203      Down-regulation     −1.203614666    1.33E-07
  PGM5-AS1                                                            572558      Down-regulation     −1.248531249    6.67E-06
  OTX2-AS1                                                            100309464   Down-regulation     −1.26206851     1.89E-05
  RNF139-AS1                                                          101927612   Down-regulation     −1.383351463    1.96E-10
  TDRG1[\*](#tfn2-medscimonit-26-e919871){ref-type="table-fn"}        732253      Down-regulation     −1.399211813    2.00E-05
  ELOVL2-AS1                                                          100506409   Down-regulation     −1.472180825    6.24E-09
  LINC01137                                                           728431      Down-regulation     −1.613551017    1.38E-09
  FAM13A-AS1[\*](#tfn2-medscimonit-26-e919871){ref-type="table-fn"}   285512      Down-regulation     −1.689264402    5.73E-09
  SPAG5-AS1[\*](#tfn2-medscimonit-26-e919871){ref-type="table-fn"}    100506436   Down-regulation     −1.774851965    1.87E-11
  MIR124-2HG                                                          100130155   Down-regulation     −1.894825134    3.78E-10
  AC005592[\*](#tfn2-medscimonit-26-e919871){ref-type="table-fn"}     101926975   Down-regulation     −2.035310985    1.55E-07
  RBFADN                                                              100506070   Down-regulation     −2.175539179    4.42E-13
  LINC00844                                                           100507008   Down-regulation     −2.290846454    1.01E-08

PVR -- proliferative vitreoretinopathy; N -- normal human retinas.

Represents the lncRNA taking part in the ceRNA network.

###### 

lncRNAs and specific targeted miRNAs in ceRNA network.

  lncRNA       miRNA
  ------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  TDRG1        miR-17-5p, miR-20b-5p, miR-27a-3p, miR-125a-5p, miR-125b-5p
  HCP5         miR-137, miR-139-5p, miR-140-5p, miR-17-5p, miR-20b-5p, miR-216b-5p, miR-22-3p, miR-23b-3p, miR-24-3p, miR-363-3p, miR-1297, miR-27a-3p, miR-107, miR-425-5p, miR-125a-5p, miR-125b-5p, miR-10a-5p
  JPX          miR-301b-3p, miR-140-5p, miR-193a-3p, miR-216b-5p, miR-23b-3p, miR-24-3p, miR-363-3p, miR-449c-5p, miR-129-5p
  MIAT         miR-301b-3p, miR-139-5p, miR-140-5p, miR-17-5p, miR-20b-5p, miR-206, miR-613, miR-216b-5p, miR-22-3p, miR-23b-3p, miR-24-3p, miR-363-3p, miR-27a-3p, miR-107, miR-449c-5p, miR-125a-5p, miR-125b-5p, miR-10a-5p,miR-129-5p
  SPAG5-AS1    miR-17-5p, miR-20b-5p, miR-429, miR-217, miR-24-3p, miR-107, miR-425-5p
  AC005592     miR-139-5p, miR-17-5p, miR-20b-5p, miR-206, miR-613, miR-216b-5p, miR-107, miR-425-5p, miR-125a-5p, miR-125b-5p, miR-137, miR-140-5p, miR-429, miR-23b-3p, miR-363-3p, miR-33a-3p, miR-10a-5p, miR-129-5p
  CRNDE        miR-140-5p, miR-142-3p, miR-193a-3p, miR-216b-5p, miR-217, miR-22-3p, miR-23b-3p, miR-363-3p, miR-1297, miR-27a-3p, miR-129-5p
  FAM13A-AS1   miR-137, miR-139-5p, miR-142-3p, miR-17-5p, miR-20b-5p, miR-217, miR-22-3p, miR-23b-3p, miR-24-3p, miR-363-3p, miR-107, miR-449c-5p, miR-125a-5p, miR-125b-5p, miR-129-5p
  AP000462     miR-17-5p, miR-20b-5p, miR-1297, miR-206, miR-613, miR-22-3p, miR-24-3p, miR-449c-5p, miR-1297

###### 

miRNAs and specific targeted mRNAs in ceRNA network.

  miRNA         mRNA
  ------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  miR-107       VCAN, TGFBR3, GABRB1, ITGA2, LCOR, PLEKHF2,PCSK5
  miR-10a-5p    ELOVL2
  miR-125a-5p   TMEM136, EIF4EBP1, MTUS1, TMEM136, STAT3, LIPA, EIF4EBP1
  miR-129-5p    SPRY4, C1S
  miR-1297      ADM, CKS2, MAN2A1
  miR-137       GLIPR1
  miR-139-5p    LCOR, ZBTB34
  miR-140-5p    LAMC1
  miR-142-3p    EGR2, ZNF217, LCOR, MTUS1
  miR-17-5p     TMEM123, CDKN1A, PLS1, NETO2, FJX1, CCND1, FAM57A, FAM129A, RAPGEF4, SLC16A9, CYBRD1, PPP3R1, PLEKHO2, CADM2, BTN3A1, STAT3, WEE1, TXNIP, SSX2IP, LCOR, TMEM138
  miR-193a-3p   LAMC1
  miR-206       GJA1, KCNJ2, CERS2, BDNF, SFRP1, WEE1
  miR-20b-5p    TXNIP, CADM2, RAPGEF4, CCND1, TMEM123, SLC16A9, PLEKHO2, FJX1, SSX2IP, STAT3, CYBRD1, PPP3R1, CDKN1A, PLS1, BAMBI, NETO2, FAM129A
  miR-216b-5p   SMAD1
  miR-217       NR4A2
  miR-22-3p     RGS2, CSF1R
  miR-23b-3p    GJA1
  miR-24-3p     GBA2, SCML1, MLEC, ZNF217, ADD1, FSCN1
  miR-27a-3p    PPIF, TGFBR3, LPCAT1, PHLPP2, PLXND1, ADD1, WEE1, ADORA2B
  miR-301b-3p   GRB10, PRUNE2, TRPC3, IRF1
  miR-33a-3p    PPP3R1
  miR-363-3p    CNNM4, PDPN, GFPT2, PHLPP2, LHFPL2
  miR-425-5p    LCOR, RAB31
  miR-429       TPD52L1
  miR-449c-5p   MYC
  miR-613       CERS2, WEE1
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